Antisense therapeutics and the treatment of CNS disease

Frontiers in Bioscience

Volumn 9, Issue , 2004, Pages 1720-1727

  Jaeger, Laura B ^a   Banks, William A ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Internal Medicine ^*  (United States)

Author keywords

Antisense; Blood brain barrier; Brain; Central nervous system; Oligonucleotide; Review

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PROTEIN; ANTISENSE OLIGONUCLEOTIDE; DEOXYRIBONUCLEOTIDE; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN P; PEPTIDE NUCLEIC ACID; PHOSPHOROTHIOIC ACID; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN MCL 1; VIRUS DNA;

ALZHEIMER DISEASE; B CELL LYMPHOMA; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CANCER THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICAL MODIFICATION; DNA TRANSCRIPTION; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS; MELANOMA CELL; NONHUMAN; RECEPTOR GENE; REVIEW; T LYMPHOCYTE; ANIMAL; CENTRAL NERVOUS SYSTEM TUMOR; CHEMISTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

HUMAN IMMUNODEFICIENCY VIRUS;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASES; CENTRAL NERVOUS SYSTEM NEOPLASMS; HIV INFECTIONS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 2442682040     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1337     Document Type: Review

References (47)

1. Agrawal, S., Z. Jiang, Q. Zhao, D. Shaw, Q. Cai, A. Roskey, L. Channavajjala, C. Saxinger and R. Zhang: Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci U S A 94, 2620-2625 (1997)
2. Alahari, S. K., N. M. Dean, M. H. Fisher, R. Delong, M. Manoharan, K.L. Tivel and R.L. Juliano: Inhibition of expression of the multidrug resistance-associated P-glycoprotein by phosphorothioate and 5′ cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol 50, 808-819 (1996)
3. Banks, W. A., S. A. Farr, W. Butt, V. B. Kumar, M. W. Franko and J. E. Morley: Delivery across the blood-brain barrier of antisense directed against amyloid β: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. J Pharmacol Exp Ther 297, 1113-1121 (2001)
4. Banks, W. A., E. O. Freed, K. A. Wolf, S. M. Robinson, M. Franko and V. B. Kumar: Transport of human immunodeficiency virus type 1 pseudoviruses across the blood-brain barrier: role of envelope proteins and adsorptive endocytosis. J Virol 75, 4681-4691 (2001)
5. Bertram, J., K. Palfner, M. Killian, W. Brysch, K. H. Schlingensiepen, W. Hiddemann and M. Kneba: Reversal of multidrug resistance in vitro by phosphorothioate oligonucleotides and ribozymes. Anticancer Drugs 6, 124-134 (1995)
6. Boado, R. J. Antisense drug delivery through the blood-brain barrier. Adv Drug Del Rev 15, 73-107 (1995)
7. Boado, R. J., Y. S. Kang, D. Wu and W. M. Pardridge: Rapid plasma clearance and metabolism in vivo of a phosphorothioate oligodeoxynucleotide with a single, internal phosphodiester bond. Drug Metab Dispos 23, 1297-1300 (1995)
8. Brigui, I., T. Djavanbakht-Samani, B. Joll̀es, S. Pigaglio and A. Laigle: Minimally modified phosphodiester antisense oligodeoxyribonucleotide directed against the multidrug resistance gene mdrl. Biochem Pharm 65, 747-754 (2003)
9. Cashion, M. F., W. A. Banks, K. L. Bost and A. J. Kastin: Transmission routes of HIV-1 gp120 from brain to lymphoid tissues. Brain Res 822, 26-33 (1999)
10. Chikhale, E. G., K. Y. Ng, P. S. Burton and R. T. Borchardt: Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides. Pharm Res 11, 412-419 (1994)
11. Christensen, H. N: Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 70, 43-77 (1990)
12. Cornford, E. M: The blood-brain barrier, a dynamic regulatory interface. Mol Physiol 7, 219-260 (1985)
13. Crooke, S. T: Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32, 329-376 (1992)
14. Demidov, V. V., V. N. Potaman, M. D. Frank-Kamenetskii, M. Egholm, O. Buchard, S. H. Sonnichsen and P. E. Nielsen: Stability of peptide nucleic acids in human serum and cellular extracts. Biochem Pharm 48, 1310-1313 (1994)
15. Egholm, M., O. Buchardt, L. Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden and P. E. Nielsen: PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen bonding rules. Nature 365, 566-568 (1993)
16. Emerman, M. and M. H. Malim: HIV-1 Regulatory/Accessory Genes: Keys to Unraveling Viral and Host Cell Biology. Science 280, 1880-1884 (1998)
17. Geary, R. S., T. A. L. Truong Watanabe, S. M. E. A. Lesnik Freier, N. B. H. Sasmor Sioufi, M. Manoharan, A. A. Levin: Pharmokinetic properties of 2′-O-(-2-methoxyethyl)-modified oligonucleotide analogues in rats. J Pharmacol Exp Ther 296, 890-897 (2001)
18. Glenner, G. G., C. W. Wong: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem and Biophys Res Comm 120, 885-890 (1994)
19. Greig, M. J., H. Gaus, L. L. Cummins, H. Sasmor and R. H. Griffey: Measurement of macromolecular binding using electrospray mass spectrometry. Determination of disassociation constants for oligonucleotide:serum albumin complexes. J Am Chem Soc 117, 10765-10766 (1995)
20. Hamma, T., A. Saleh, I. Huq, T. M. Rana and P. S. Miller: Inhibition of HIV Tat-TAR interactions by an antisense oligo-2′-O-methylribonucleoside methylphosphonate. Bioorg Med Chem Lett 13, 1845-1848 (2003)
21. Hausen, P., H. Stein and H. Ribonuclease: Enzyme degrading the RNA moiety of DNA/RNA hybrids. Eur J Biochem 14, 278-283 (1970)
22. Herdewijn, P: Heterocyclic modifications of oligonucleotides and antisense technology. Antisense and Nucleic Acid Drug Dev 10, 297-310 (2000)
23. Jones, K. A. and B. M. Peterlin: Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem 63, 717-743 (1994)
24. Kalaria, R. N., S. A. Gravina, J. W. Schmidley, G. Perry and S. I. Harik: The glucose transporter of the human brain and blood-brain barrier. Ann Neurol 24, 757-764 (1988)
25. Kaufmann, S. H., J. E. Karp, P. A. Svingen, S. Krajewski, P. J. Burke, S. D. Gore and J. C. Reed: Elevated expression of the apoptotic regulator Mcl-1at the time of leukemic relapse. Blood 91, 991-1000 (1998)
26. Keep, R. F. and H. C. Jones: A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries and ventricular ependyma in the rat. Brain Res Dev Brain Res 56, 47-53 (1990)
27. Khatsenko, O., R. Morgan, L. Truong, C. York-Defalco, H. Sasmor, B. Conklin and R. S. Geary: Absorption of antisense oligonucleotides in rat intestine: effect of chemistry and length. Antisense and Nucleic Acid Drug Dev 10, 35-44 (2000)
28. Masters, C. L., G. Simms, N. A. Weinman, G. Multhaup, B. L. McDonald and K. Beyreuther: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82, 4245-4249 (1985)
29. McMahon, B. M., J. Stewart, A. Fauq, S. Younkin, L. Younkin and E. Richelson: Using peptide nucleic acids as gene-expression modifiers to reduce β-amyloid levels. J Mol Neurosci 19, 71-76 (2002)
30. McMahon, B. M., J. A. Stewart, J. Jackson, A. Fauq, D. J. McCormick and E. Richelson: Intraperitoneal injection of antisense peptide nucleic acids targeted to the mu receptor decreases response to morphine and receptor protein levels in rat brain. Brain Res 904, 345-349 (2001)
31. Miller, D. L., I. A. Papayannopoulos, J. Styles, S. A. Bobin, Y. Y. Lin, K. Biemann and K. Iqbal: Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 301, 41-52 (1993)
32. Moses, A. V., F. E. Bloom, C. D. Pauza and J. A. Nelson: Human immunodeficiency virus infection of human brain capillary endothelial cells occurs via a CD4/galactosylceramide-independent mechanism. Proc Natl Acad Sci U S A 90, 10474-10478 (1993)
33. Nielsen, P. E., M. Egholm, R. H. Berg and O. Buchardt: Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254, 1497-1500 (1991)
34. Oldendorf, W. H: Lipid-solubility and drug penetration of the blood-brain barrier. Proc Soc Exp Biol Med 147, 813-816 (1973)
35. Pardridge, W. M., R. J. Boado and C. R. Farrell: Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization. J Biol Chem 265, 18035-18040 (1990)
36. Pardridge, W. M., R. J. Boado and Y. S. Kang: Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc Natl Acad Sci U S A 92, 5592-5596 (1995)
37. Prelli, F., E. M. Castaño, G. G. Glenner and B. Frangione: Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem 51, 648-651 (1988)
38. Reed, J. C: Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 9, 451-473 (1995)
39. Shoji, M., T. E. Golde, J. Ghiso, T. T. Cheung, S. Estus, L. M. Shaffer, X. D. Cai, D. M. McKay, R. Tintner and Frangione, B: Production of the Alzheimer amyloid-β protein by normal proteolytic processing. Science 258, 1598-1603 (1992)
40. Stein, C. A. and Y. C. Cheng: Antisense oligonucleotides as therapeutic agents: is the bullet really magical? Science 261, 1004-1012 (1993)
41. Strasser, A., D. C. Huan and, D. L. Vaux: The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim Biophys Acta 1333, F151-F178 (1997)
42. Thallinger, C., M. F. Wolschek, V. Wacheck, H. Maierhofer, P. Günsberg, P. Polterauer, H. Pehamberger, B. P. Monia, E. Selzer, K. Wolff and B. Jansen: Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol 120, 1081-1086 (2003)
43. Thomas, S. A. and M. B. Segal: The transport of the anti-HIV drug, 2′,3′-didehydro-3′-deoxythymidine (D4T), across the blood-brain and blood-cerebrospinal fluid barriers. Br J Pharmacol 125, 49-54 (1998)
44. Tyler-McMahon, B. M., J. A. Stewart, J. Jackson, M. D. Bitner, A. Fauq, D. J. McCormick and E. Richelson: Altering behavioral responses and dopamine transporter protein with antisense peptide nucleic acids. Biochem Pharm 62, 929-932 (2001)
45. Tyler, B.M., K. Jansen, D.J. McCormick, C.L. Douglas, M. Boules, J.A. Stewart, L. Zhao, B. Lacy, B. Cusack, A. Fauq and E. Richelson: Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. Proc Natl Acad Sci U S A 96, 7053-7058 (1999)
46. White, A.R., R. Reyes, J.F. Mercer, J. Camakaris, H. Zheng, A.I. Bush, G. Multhaup, K. Beyreuther, C.L. Masters, R. Cappai: Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res 842, 439-444 (1999)
47. Zou, K., J. S. Gong, K. Yanagisawa amd M. Michikawa: A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J Neurosci 22, 4833-4841 (2002)